117 related articles for article (PubMed ID: 38334731)
1. [Is it possible to detect surface antigen CD133 on patient-derived glioblastoma continuous cell cultures using fluorescent aptamers?].
Moiseenko VL; Antipova OM; Pavlova SA; Pronin IN; Pavlova GV; Kopylov AM
Zh Vopr Neirokhir Im N N Burdenko; 2024; 88(1):56-62. PubMed ID: 38334731
[TBL] [Abstract][Full Text] [Related]
2. RNA Aptamers for Theranostics of Glioblastoma of Human Brain.
Kopylov AM; Fab LV; Antipova O; Savchenko EA; Revishchin AV; Parshina VV; Pavlova SV; Kireev II; Golovin AV; Usachev DY; Pavlova GV
Biochemistry (Mosc); 2021 Aug; 86(8):1012-1024. PubMed ID: 34488577
[TBL] [Abstract][Full Text] [Related]
3. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.
Ma HI; Chiou SH; Hueng DY; Tai LK; Huang PI; Kao CL; Chen YW; Sytwu HK
J Neurosurg; 2011 Mar; 114(3):651-62. PubMed ID: 21054139
[TBL] [Abstract][Full Text] [Related]
4. Glioblastoma cells negative for the anti-CD133 antibody AC133 express a truncated variant of the CD133 protein.
Osmond TL; Broadley KW; McConnell MJ
Int J Mol Med; 2010 Jun; 25(6):883-8. PubMed ID: 20428792
[TBL] [Abstract][Full Text] [Related]
5. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors.
Yi JM; Tsai HC; Glöckner SC; Lin S; Ohm JE; Easwaran H; James CD; Costello JF; Riggins G; Eberhart CG; Laterra J; Vescovi AL; Ahuja N; Herman JG; Schuebel KE; Baylin SB
Cancer Res; 2008 Oct; 68(19):8094-103. PubMed ID: 18829568
[TBL] [Abstract][Full Text] [Related]
6. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.
Pallini R; Ricci-Vitiani L; Montano N; Mollinari C; Biffoni M; Cenci T; Pierconti F; Martini M; De Maria R; Larocca LM
Cancer; 2011 Jan; 117(1):162-74. PubMed ID: 20806346
[TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas.
Garcia JL; Perez-Caro M; Gomez-Moreta JA; Gonzalez F; Ortiz J; Blanco O; Sancho M; Hernandez-Rivas JM; Gonzalez-Sarmiento R; Sanchez-Martin M
BMC Cancer; 2010 Aug; 10():454. PubMed ID: 20735813
[TBL] [Abstract][Full Text] [Related]
8. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP
Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311
[TBL] [Abstract][Full Text] [Related]
9. Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas.
Shin JH; Lee YS; Hong YK; Kang CS
J Neurooncol; 2013 Dec; 115(3):333-41. PubMed ID: 24129546
[TBL] [Abstract][Full Text] [Related]
10. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
Metellus P; Nanni-Metellus I; Delfino C; Colin C; Tchogandjian A; Coulibaly B; Fina F; Loundou A; Barrie M; Chinot O; Ouafik L; Figarella-Branger D
Ann Surg Oncol; 2011 Oct; 18(10):2937-45. PubMed ID: 21479688
[TBL] [Abstract][Full Text] [Related]
12. Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma.
Hermansen SK; Christensen KG; Jensen SS; Kristensen BW
J Histochem Cytochem; 2011 Apr; 59(4):391-407. PubMed ID: 21411810
[TBL] [Abstract][Full Text] [Related]
13. [A novel adherent culture method of glioblastoma cells expressing CD133 using collagen-1-coated plates].
Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Houkin K
Hokkaido Igaku Zasshi; 2012 Aug; 87(4-5):147-51. PubMed ID: 23016266
[TBL] [Abstract][Full Text] [Related]
14. Type 1 collagen as a potential niche component for CD133-positive glioblastoma cells.
Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Houkin K
Neuropathology; 2014 Aug; 34(4):378-85. PubMed ID: 24673436
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and characterization of CD133 targeted aptamer-drug conjugates for precision therapy of anaplastic thyroid cancer.
Ge MH; Zhu XH; Shao YM; Wang C; Huang P; Wang Y; Jiang Y; Maimaitiyiming Y; Chen E; Yang C; Naranmandura H
Biomater Sci; 2021 Feb; 9(4):1313-1324. PubMed ID: 33350399
[TBL] [Abstract][Full Text] [Related]
16. [Adherent culture of CD133+ cells in glioblastomas and expression of ADLH1].
Wang P; Mao Q; Wang X; Chen MN; Gan LA; Liu YH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 May; 42(3):413-6. PubMed ID: 21827011
[TBL] [Abstract][Full Text] [Related]
17. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.
Liu G; Yuan X; Zeng Z; Tunici P; Ng H; Abdulkadir IR; Lu L; Irvin D; Black KL; Yu JS
Mol Cancer; 2006 Dec; 5():67. PubMed ID: 17140455
[TBL] [Abstract][Full Text] [Related]
18. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
Brown DV; Daniel PM; D'Abaco GM; Gogos A; Ng W; Morokoff AP; Mantamadiotis T
Oncotarget; 2015 Mar; 6(8):6267-80. PubMed ID: 25749043
[TBL] [Abstract][Full Text] [Related]
19. Investigating the link between molecular subtypes of glioblastoma, epithelial-mesenchymal transition, and CD133 cell surface protein.
Zarkoob H; Taube JH; Singh SK; Mani SA; Kohandel M
PLoS One; 2013; 8(5):e64169. PubMed ID: 23734191
[TBL] [Abstract][Full Text] [Related]
20. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells.
Wang J; Sakariassen PØ; Tsinkalovsky O; Immervoll H; Bøe SO; Svendsen A; Prestegarden L; Røsland G; Thorsen F; Stuhr L; Molven A; Bjerkvig R; Enger PØ
Int J Cancer; 2008 Feb; 122(4):761-8. PubMed ID: 17955491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
